Melanoma circulating tumor cells: Benefits and challenges required for clinical application

作者：Marsavela, G.; Aya-Bonilla, C. A.^*; Warkiani, M. E.; Gray, E. S.; Ziman, M.

来源：Cancer Letters, 2018, 424: 1-8.

DOI：10.1016/j.canlet.2018.03.013

• Circulating tumor cells
• Biomarker
• Melanoma
• Cancer
• Liquid biopsy

The implementation of novel therapeutic interventions has improved the survival rates of melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses. Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma CTCs (MeICTCs) is still unclear due to challenges that appear intrinsic to Me1CTCs (i.e. rarity, heterogeneity) and a lack of standardization in their isolation, across research laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC isolation and address their potential role in melanoma management.

• 出版日期2018